Last reviewed · How we verify
Nepafenac (Nevanac)
Nepafenac (Nevanac) is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Center For Excellence In Eye Care. It is currently FDA-approved for Pain and inflammation associated with cataract surgery, Reduction of ocular inflammation following cataract surgery.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye.
Nepafenac, also known as Nevanac, is a small molecule cyclooxygenase inhibitor used to treat various eye conditions. It is indicated for conditions such as cataract, macular edema, myopia, hyperopia, and cystoid macular edema, among others.
At a glance
| Generic name | Nepafenac (Nevanac) |
|---|---|
| Sponsor | Center For Excellence In Eye Care |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Nepafenac is a prodrug that is converted to amfenac in ocular tissues. It works by inhibiting COX-1 and COX-2 enzymes, thereby reducing the synthesis of inflammatory prostaglandins. This mechanism reduces ocular inflammation, pain, and swelling associated with cataract surgery and other inflammatory eye conditions.
Approved indications
- Pain and inflammation associated with cataract surgery
- Reduction of ocular inflammation following cataract surgery
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Photophobia
- Corneal erosion or ulceration
Key clinical trials
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (PHASE2)
- DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC) (PHASE4)
- Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) (PHASE4)
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension (PHASE3)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
- Post Intravitreal Injection Topical NSAID vs. Patching (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nepafenac (Nevanac) CI brief — competitive landscape report
- Nepafenac (Nevanac) updates RSS · CI watch RSS
- Center For Excellence In Eye Care portfolio CI
Frequently asked questions about Nepafenac (Nevanac)
What is Nepafenac (Nevanac)?
How does Nepafenac (Nevanac) work?
What is Nepafenac (Nevanac) used for?
Who makes Nepafenac (Nevanac)?
What drug class is Nepafenac (Nevanac) in?
What development phase is Nepafenac (Nevanac) in?
What are the side effects of Nepafenac (Nevanac)?
What does Nepafenac (Nevanac) target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting Cyclooxygenase (COX-1 and COX-2)
- Manufacturer: Center For Excellence In Eye Care — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Pain and inflammation associated with cataract surgery
- Indication: Drugs for Reduction of ocular inflammation following cataract surgery
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing